Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials

@article{Allemann2006FibratesIT,
  title={Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials},
  author={Sabin Allemann and Peter Diem and Matthias Egger and Emanuel R Christ and Christoph Stettler},
  journal={Current Medical Research and Opinion},
  year={2006},
  volume={22},
  pages={617 - 623}
}
ABSTRACT Objective: To assess the impact of lipid lowering treatment with fibrates on cardiovascular endpoints in patients with type 2 diabetes mellitus. Methods: MEDLINE (from inception to November 2005) and the Cochrane Controlled Trials Register (including Issue 3, 2005) were searched for randomised controlled trials comparing therapy with fibrates to placebo in patients with type 2 diabetes mellitus. Electronic searches were supplemented by manual searching of reference lists, reviews… 
View on Taylor & Francis
ncbi.nlm.nih.gov
25 Citations
Background Citations
6
Methods Citations
1

25 Citations

Citation Type

Citation Type

Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives
TLDR
There is a need for rigorous evaluations of new therapeutic approaches in both primary and secondary prevention of stroke and management of acute stroke in patients with type 2 diabetes, and potential strategies for improving outcomes are highlighted.
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Secondary prevention of stroke.
TLDR
Information is provided on risk factor management programs, management of hypertension, diabetes, hyperlipidemia, the role of infection, lifestyle modification (diet, smoking, use of alcohol, physical activity) as well as treatment for atherosclerosis and cardiac abnormalities and reperfusion techniques.
Nonstatin therapies for management of dyslipidemia: a review.
Approaches to Prevention of Cardiovascular Complications and Events in Diabetes Mellitus
TLDR
Prevention of major cardiovascular events with the antithrombotic agent aspirin (acetylsalicylic acid) is widely recommended, but reportedly underutilised in patients with diabetes, as well as in slowing progression of retinopathy.
Evidence based diabetology : strategies to prevent macrovascular disease and to reduce mortality
TLDR
This thesis was on prevention and therapy of macrovascular disease in patients with type 1 and type 2 DM, as well as on comparisons with patients without DM, and whether the effectiveness of certain treatment forms differs between patients with and without DM.
Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study.
Cardiorenal Interaction: Appropriate Treatment of Cardiovascular Risk Factors to Improve Outcomes in Chronic Kidney Disease
TLDR
CVD outcomes have been shown to improve with the treatment of risk factors commonly found in association with CKD, including hypertension, diabetes, dyslipidemia, albuminuria, and smoking, as well as appropriate renin-angiotensin-aldosterone system blockade and antiplatelet therapy.
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)
TLDR
Predictors of stroke and the effect of atorvastatin on specific stroke subtypes in Type 2 diabetes in the Collaborative AtorVastatin Diabetes Study (CARDS) are examined.
...
1
2
3
...

References

SHOWING 1-10 OF 37 REFERENCES
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study
TLDR
Improving dyslipidemia in type 2 diabetic subjects had no effect on the progress of ultrasonically measured arterial disease, although the lower rate of “definite CHD events” in the treated group suggests that this might result in a reduction in the incidence of coronary heart disease.
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
Effect of different antilipidemic agents and diets on mortality: a systematic review.
The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization
TLDR
The protocol of the first intervention trial designed to examine directly whether correcting dyslipoproteinaemia in men and women with NIDDM will reduce their coronary artery disease is described.
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
TLDR
Results are in accord with two previous trials with different pharmacologic agents and indicate that modification of lipoprotein levels with gemfibrozil reduces the incidence of coronary heart disease in men with dyslipidemia.
Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study
TLDR
Compared with similarly dyslipidemic nondiabetic subjects, patients with NIDDM are at markedly increased risk of CHD and this elevated risk can be somewhat reduced by gemfibrozil.
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
TLDR
Bezafibrate has no effect on the incidence of coronary heart disease and of stroke combined but may reduce the incidenceof non-fatal coronary events, particularly in those aged <65 years at entry, in whom all coronary events may also be reduced.
...
1
2
3
4
...